Top in allergy/asthma: Safety of cephalosporins; barriers to shared decision-making
Click Here to Manage Email Alerts
The safety of cephalosporins for patients with confirmed penicillin allergies has not been well studied, but they appeared to be safe in a small study.
It was the top story in allergy/asthma last week.
Another top story was about the disconnect between allergists and patients over whether they believed they were being engaged in shared decision-making regarding treatment.
Read these and more top stories in allergy/asthma below:
Q&A: Patients with verified penicillin allergies safely receive cephalosporins
High-risk patients who had a verified penicillin allergy safely received cephalosporins, according to a letter published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Disconnects between allergists, patients impact shared decision-making
There was a disconnect between allergists and patients in their perceptions of shared decision-making, according to a survey published in World Allergy Organization Journal. Bill Sanders, DMS, PA-C, and Michael S. Blaiss, MD, FACAAI, FAAAAI, weighed in with their perspectives. Read more.
Increased Cladosporium abundance associated with poor asthma control
Cladosporium was more abundant in the lungs of patients with poor asthma control compared with patients who had better control, according to a poster presented at the CHEST Annual Meeting. Read more.
Q&A: Nasal spray effectively fills need for needleless epinephrine delivery
The neffy epinephrine nasal spray from ARS Pharma produced pharmacokinetic and pharmacodynamic responses that were comparable with injected delivery, according to a study. Read more.
Rush-induction protocol enables safe aeroallergen immunotherapy
A four-step rush-induction protocol ending with 0.05 mL of the 1:10 v/v concentration was safe for patients at the beginning of aeroallergen therapy, researchers said. Read more.